Fridge-Free Tetanus Vaccine Passes First Human Trial
Researchers said the room-temperature vaccine matched licensed boosters in 60 adults and could reduce waste from cold-chain failures.
- On Wednesday, August 5, 2026, scientists published Phase 1 results in a Lancet journal showing the SPVX02 tetanus-diphtheria vaccine remains safe and stable at room temperature, potentially eliminating strict refrigeration requirements.
- Currently, many vaccines are wasted globally each year due to temperature fluctuations, as most require strict Cold-chain refrigeration from manufacture to administration, creating logistical challenges in remote regions.
- The trial at the NIHR Clinical Research Facility in Southampton involved 60 healthy adults, comparing the SPVX02 formula against licensed vaccines using trehalose, a special sugar to protect vital components.
- Prof Saul Faust, Director of the NIHR Clinical Research Facility, said the vaccine provided "equivalent" immune responses and was "safe and well tolerated," while Unicef's Ephrem Tekle Lemango noted the innovation could expand global immunization.
- To further evaluate the vaccine's performance and address questions about long-term effectiveness in diverse populations, scientists plan to launch a larger trial involving 160 people in the coming months.
10 Articles
10 Articles
Fridge-free tetanus-diphtheria vaccine shows promise of reaching millions worldwide
The encouraging results of the world's first trial of a fridge-free tetanus-diphtheria vaccine could improve access worldwide to crucial treatments while reducing carbon emissions. Fridge-free vaccines have the potential to transform vaccine delivery by reducing dependence on refrigeration. This would improve access in more isolated communities and cut the environmental impact by reducing energy use and emissions.
This article was originally published on Cedarnews.net. For more news and exclusive reports, visit our website. NIHR: A woman participated in the clinical trial for the vaccines in April 2025. British scientists have successfully tested a vaccine that does not require refrigeration on volunteers for the first time, a step that could revolutionize vaccine storage and transportation, and reduce the amount of doses wasted annually. Most vaccines cu…
“Fridge-free” vaccine for tetanus-diphtheria shows promise in first human trial
A tetanus-diphtheria vaccine that can be stored at room temperature has shown promising early results in a development hailed as a potential “game changer” for global health. Maintaining the cold chain for vaccines is a significant challenge in resource poor countries, remote communities, and regions affected by conflict.
Fridge-free vaccine trial shows ‘encouraging results’
A clinical trial testing a fridge-free tetanus and diphtheria vaccine has shown ‘encouraging’ early results and has progressed to the next stage, the National Institute of Health and Care Research (NIHR) has confirmed. The phase I study, which completed in March, shows the SPVX02 vaccine remains effective without refrigeration even after long-term storage at 30°C for two years.
uhs.nhs.uk
nihr.ac.ukFridge-free vaccine shows promise for reaching millions more people worldwide
The world-first trial of a fridge-free tetanus-diphtheria vaccine at University Hospital Southampton (UHS) has produced encouraging results that could improve access worldwide to crucial treatments. Around half of vaccines are wasted globally each year, according to the World Health Organization. Millions of vaccine doses are lost because of temperature changes during storage and transport.
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
